The historical rank and industry rank for Northwest Biotherapeutics's Price-to-Tangible-Book or its related term are showing as below:
NWBO's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.81 * Ranked among companies with meaningful Price-to-Tangible-Book only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Northwest Biotherapeutics's Price-to-Tangible-Book
For the Biotechnology subindustry, Northwest Biotherapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Northwest Biotherapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Northwest Biotherapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Northwest Biotherapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Northwest Biotherapeutics (Northwest Biotherapeutics) Business Description
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NWBO has been successfully added to your 